original ) (raw )Lixisenatide reduces glycemic variability in insulin-treated patients with type 2 diabetes
ENDOCARE ERIC
Diabetes, obesity & metabolism, 2017
View PDFchevron_right
REAL WORLD EFFECTIVENESS OF LIXISENATIDE AND OTHER INTENSIFICATION THERAPY IN THE MANAGEMENT OF TYPE 2 DIABETIC PATIENTS UNCONTROLLED WITH BASAL INSULIN.
IJAR Indexing
View PDFchevron_right
The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes: a multi-center observational study
Sanja Klobucar Majanovic
Diabetology & metabolic syndrome, 2018
View PDFchevron_right
Mechanisms and Clinical Efficacy of Lixisenatide for the Management of Type 2 Diabetes
Michael Horowitz
Advances in Therapy, 2013
View PDFchevron_right
Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in Type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)
Paramesh Shamanna
Journal of Diabetes and its Complications, 2014
View PDFchevron_right
Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial
Julio Rosenstock
Diabetes Care, 2015
View PDFchevron_right
Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials
Julio Rosenstock , Riccardo Bonadonna
Journal of Diabetes and its Complications, 2014
View PDFchevron_right
Long-term safety of once-daily lixisenatide in Japanese patients with type 2 diabetes mellitus: GetGoal-Mono-Japan
Daisuke Yabe
View PDFchevron_right
Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: Systematic review, network meta‐analysis and cost‐effectiveness analysis
Shuli Qu
Diabetes, Obesity and Metabolism, 2019
View PDFchevron_right
Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment
Giulio Marchesini
Diabetes, obesity & metabolism, 2017
View PDFchevron_right
Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-S
Daisuke Yabe
View PDFchevron_right
Lixisenatide, a Novel GLP-1 Receptor Agonist, for the Treatment of Type 2 Diabetes
International Journal of Health Sciences and Research (IJHSR)
https://www.ijhsr.org/IJHSR\_Vol.7\_Issue.6\_June2017/IJHSR\_Abstract.046.html , 2017
View PDFchevron_right
Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis
hernando vargas-uricoechea
Diabetes Therapy, 2016
View PDFchevron_right
Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial
Sandro Gentile
Diabetes Care, 2016
View PDFchevron_right
Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
Vincent Woo
Diabetic Medicine, 2010
View PDFchevron_right
Lixisenatide for Type 2 Diabetes Mellitus Patients Inadequately Controlled on Oral Antidiabetic Drugs: A Mixed-Treatment Comparison Meta-analysis and Cost–Utility Analysis
Shuli Qu
Diabetes Therapy, 2020
View PDFchevron_right
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Jeffrey Probstfield
New England Journal of Medicine, 2015
View PDFchevron_right
Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin
Sergiy Dotsenko
Diabetes Care, 2013
View PDFchevron_right
Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
Laura Maffei
Diabetes Care, 2013
View PDFchevron_right
Dose‐dependent effects of the once‐daily GLP‐1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, …
Freddy Eliaschewitz
Diabetic Medicine, 2010
View PDFchevron_right
Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials
Jean-françois Yale
Journal of diabetes and its complications, 2016
View PDFchevron_right
Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M
Aniceto Leguizamo Dimas
2013
View PDFchevron_right
Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of lixisenatide and other glucagon-like peptide-1 receptor agonists
Sandro Gentile
Diabetes/Metabolism Research and Reviews, 2016
View PDFchevron_right
Real-World Effectiveness and Safety of Lixisenatide as Add-On to Oral Antidiabetic Drugs as Part of Routine Clinical Practice in Bulgaria: LIXODAR Study
Veselina Pehlivanova
Diabetes Therapy, 2019
View PDFchevron_right
Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed‐ratio combination: a post hoc analysis of the LixiLan‐O and LixiLan‐L trials
Jaime Davidson
Diabetic Medicine
View PDFchevron_right
More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L
Raffaele Napoli
Diabetes, Obesity and Metabolism, 2018
View PDFchevron_right
Effect of a single dose of insulin glargine/lixisenatide fixed ratio combination (iGlarLixi) on postprandial glucodynamic response in Japanese patients with type 2 diabetes mellitus: A phase I randomized trial
Roland Wesch
Diabetes, Obesity and Metabolism, 2019
View PDFchevron_right
Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes
Riccardo Perfetti
Diabetes, obesity & metabolism, 2018
View PDFchevron_right
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial
Riccardo Perfetti
Diabetes care, 2016
View PDFchevron_right
Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial
Carol Wysham
Diabetes, obesity & metabolism, 2017
View PDFchevron_right